Invivogen
Menu

Overview of Regulated Cell Death

Last updated: July 2021

Cell death as an innate immune response

Regulated cell death (RCD) is a lethal process taking place in the context of stressful stimuli (e.g. infections, metabolic disorders, or genotoxic agents) for which no restoration of cellular homeostasis could be completed [1, 2]. In contrast with accidental cell death (ACD), a biologically uncontrolled process, RCD involves tightly structured signaling cascades and molecularly defined effector mechanisms [1, 2]. There are two principal types of cell death, apoptosis, and necrosis, which mainly differ in duration, morphological aspects, and inflammatory outcomes. Necrosis has long been considered an ACD before the description of multiple regulated necrotic cell death mechanisms, including pyroptosisnecroptosis, ferroptosis, and NETosis [1-3]. ​There is evidence for extensive crosstalk between the different cell death pathways, ensuring threat best-fit responses [2, 3]. A better understanding of the molecular mechanisms underlying RCD is still required to develop efficient therapeutics for monogenic (i.e. due to the functional alteration of a gene) and inflammation-driven diseases [2].

 

APOPTOSIS

Apoptosis was the first well-defined process of regulated cell death [1-3]. It is triggered either homeostatically (e.g. during embryonic development), or upon exposure to a variety of insults (e.g. engagement of TNF (tumor necrosis factor) family death domain receptors at the cell surface). Two primary apoptosis pathways exist, the intrinsic and extrinsic pathways. The intrinsic pathway is engaged by a variety of intracellular signals and leads to the activation of Caspase-9. In contrast, the extrinsic pathway is initiated by extracellular perturbations, through death receptors, and induces the activation of Caspase-8. Both the extrinsic and intrinsic apoptotic pathways lead to the activation of Caspase-3 which cleaves more than 500 cellular substrates for death induction.
Apoptosis is a slow process (6h to ~24h) that operates through DNA fragmentation, membrane blebbing, and the formation of apoptotic bodies. Neighboring phagocytes swiftly remove the dead cells and produce anti-inflammatory cytokines.
The absence of cell lysis and material release in the extracellular milieu prevents inflammation and tissue damage, thus acknowledging apoptosis safe self-destruction. Apoptosis is thus considered a "silent" form of cell death. 

 

Inflammasome-induced pyroptotic cell death
Inflammasome-induced pyroptotic cell death

 

PYROPTOSIS

Pyroptosis is a form of regulated necrotic cell death that results from inflammasome activation [4, 5]. Inflammasomes are cytosolic multiprotein complexes generally comprised of a sensor and an inflammatory caspase connected to an adaptor protein (ASC). Their assembly can be triggered by a multitude of microbial and host-derived stimuli [4].

Typically, inflammasome activation is a two-step process [4]. A first signal (‘priming’), provided by microbial molecules such as lipopolysaccharide (LPS), induces NF-κB-dependent expression of pro-IL1β. The second signal, provided by structurally unrelated microbial molecules (e.g. Nigericin toxin) or danger signals, triggers inflammasome multimerization.

Inflammasomes are defined as 'canonical' when their assembly requires Caspase-1 (CASP-1), and as 'non-canonical' when their assembly depends on human Caspase-4 (CASP-4), Caspase-5 (CASP-5), or their murine ortholog Caspase-11 (CASP-11) [4]

Inflammasome-associated caspases mediate the proteolytic cleavage and activation of the Gasdermin D N-terminal domain (GSDMD-NT) [5]. This functional domain translocates to the plasma membrane and oligomerizes to form pores. GSDMD pore formation at the cell membrane elicits the release of  IL-1β and IL-18 pro-inflammatory cytokines, as well as alarmin or DAMPs (danger-associated molecular patterns), such as HMGB1 (high mobility group B1 protein), into the extracellular space. Accumulation of GSDMD pores causes cell swelling and formation of bubble-like herniations, ultimately leading to plasma membrane rupture (PMR) [5].

 

Read moreRead our Practical guide on Inflammasomes

 

NECROPTOSIS

Induction of necroptotic cell death
Induction of necroptotic cell death

Necroptosis is a form of regulated necrotic cell death. This pathway occurs as a backup death process when apoptosis is prevented (e.g. by pathogens or mutations). Necroptosis can be triggered upon activation of death domain receptors (e.g. TNFR1, Fas), Toll-like receptors (e.g. TLR3, TLR4), or cytosolic nucleic acid sensors (e.g. ZBP1) [6-9]. These distinct stimuli trigger the formation of different protein platforms (called necrosomes), which all rely on homotypic interactions through a RIPK homology interaction motif (RHIM) [6]. Necrosome-associated receptor-interacting protein kinase 3 (RIPK3) activates the necroptosis executioner mixed lineage kinase domain-like pseudokinase (MLKL). Activated MLKL undergoes a conformation change and translocation to the plasma membrane where it causes permeabilization and plasma membrane rupture (PMR) [6-9].

  • Downstream of TNFR1

TNF-induced necroptosis is the most studied and best characterized necroptotic pathway [6]. TNF-α- ligation to its receptor, TNFR1, induces the formation of a receptor-bound complex (complex I) where the TNFR1-associated death domain protein (TRADD) associates with the receptor-interacting serine/threonine-protein kinase 1 (RIPK1). Within complex I, RIPK1 is ubiquitinylated by cellular inhibitors of apoptosis proteins (cIAPs) and phosphorylated by IKKα and IKKβ, leading to NF-KB activation and transcription of pro-survival genes [6-9]. Cell death occurs upon loss/inhibition of cIAPs: RIPK1 dissociates from the receptor-bound complex I and is incorporated into a second complex (aka ripoptosome) together with RIPK3 and Caspase-8 (CASP-8). CASP-8 activation leads to downstream apoptosis. When CASP-8 is absent or inactivated, RIPK1 and RIPK3 form a RHIM-dependent oligomeric amyloid structure, and RIPK3 recruits MLKL to form the RIPK1-RIPK3-MLKL necrosome [6-9].

  • Downstream of TLR3 or TLR4

Similar to TNF-induced necrosome, TLR4 stimulation by LPS or TLR3 stimulation by dsRNA leads to RHIM-mediated association of the Toll-like receptor adaptor molecule TRIF with RIPK3. TRIF-RIPK3-MLKL necrosome functions independently of RIPK1 [6-9].

  • Downstream of ZBP1

The cytosolic dsDNA sensor ZBP1 (Z-DNA binding protein, aka DAI (DNA-dependent activator of IFN regulatory transcription factors)) undergoes a conformation change upon ligand binding (e.g. viral dsDNA), allowing RHIM-mediated association with RIPK3. ZBP1-RIPK3-MLKL necrosome functions independently of RIPK1 [6-9].

 

Depending on your applications, InvivoGen offers:

THP1-HMGB1-Lucia™ reporter cells
Regulated Cell Death modulators

 

Products

THP1-HMGB1-Lucia™ reporter cells Pyroptosis and necroptosis reporter monocytes
Ac-YVAD-cmk Caspase-1 inhibitor
Z-VAD-FMK Pan-caspase inhibitor
VX-765 Caspase-1 and Caspase-4 inhibitor
Necrostatin-1 Specific inhibitor of RIPK1
BV6 Inhibitor of IAPs - Smac mimetic
Z-IETD-FMK Specific inhibitor of Caspase-8

 

References

1. Tang D. et al., 2021. The molecular machinery of regulated cell death. Cell Research. 29:347-364.
2. Place D.E. and Kanneganti T-D, 2019. Cell death-mediated cytokine release and its therapeutic implications. J. Exp. Med. doi: 10.1084/jem.20181892.
3. Van Opdenbosch N. and Lamkanfi M., 2019. Caspases in cell death, inflammation, and disease. Immunity. 50:1352-1364.
4. Broz P. and Dixit V.M., 2016. Inflammasomes: mechanism of assembly, regulation and signalling. Nat Rev Immunol. 16:407-20.
5. Kovacs S.B. and Miao E.A., 2017. Gasdermins: effectors of pyroptosis. Trends Cell Biol. 27:673-84.
6. Grootjans S. et al., 2017. Initiation and execution mechanisms of necroptosis: an overview. Cell Death Differ. 24:1184-95.
7. Choi M.E. et al., 2021. Necroptosis: a crucial pathogenic mediator of human disease. JCI Insight. 4(15):e128834.
8. Bertheloot D. et al., 2021. Necroptosis, pyroptosis and apoptosis : an intricate game of cell death. Cellular & Molecular Immunology. 18:1106-1121.
9. Speir M. et al., 2021. Targeting RIP kinases in chronic inflammatory disease. Biomolecules. 11:646.

Customer Service
& Technical Support
Contact us
Shopping cart is empty